Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 9, 2026

Stagwell (STGW) Agencies Deliver Impactful Moments Around Super Bowl LX

View original at finance.yahoo.com
Stagwell (STGW) Agencies Deliver Impactful Moments Around Super Bowl LX 72andSunny, Allison, Anomaly, Code and Theory, Colle McVoy, Crispin, Gold Rabbit Sports, The Harris Poll, HarrisX, HUNTER, JetFuel, The Marketing Cloud's HarrisQuest and The People Platform, Movers+Shakers, SPORT BEACH, and TEAM delivered powerful…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stagwell punched 10 times over its weight at the Super Bowl with 10% or more of the ads

    80% confidence

  • 75% of Americans are dehydrated but don't know it

    80% confidence

  • Stagwell is the global challenger network transforming marketing through AI

    80% confidence

  • HarrisX is conducting some of the most comprehensive ad testing around the Big Game, surveying nearly 10,000 Americans

    80% confidence

  • Last year's HarrisX Ad Index crowned NFL's 'Somebody' spot as America's favorite Super Bowl ad, which went on to win a Sports Emmy for Outstanding Public Service Content

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com